恆銘達(002947.SZ)擬斥2300萬港元在港設立全資子公司主要從事進出口貿易
格隆匯8月19日丨恆銘達(002947.SZ)公佈,公司擬以自有資金或自籌資金在香港設立子公司恆世誠(香港)國際發展有限公司(擬)(暫定名,以最終註冊為準,“香港公司”),投資總額2300萬港元,公司持有香港公司100%股權,主要從事進出口貿易。
香港作為全球主要港口城市之一,在進出口貿易領域的政策、環境、傳統、人才儲蓄等方面具備深厚積累及突出優勢。為了強化公司區位優勢,提高貿易效率,擬在香港設立全資子公司以發展進出口貿易。
此次投資的資金全部來源於公司自有資金或自籌資金,符合公司的戰略發展方向,不會對公司的生產經營產生不利影響,不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.